Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed

March 30, 2026

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

March 30, 2026

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

March 30, 2026

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

March 30, 2026

Paraganglioma Market Trends and Investment Opportunities 2026-2030

March 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
Press Release

Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research

By News RoomFebruary 15, 20243 Mins Read
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
Share
Facebook Twitter LinkedIn Pinterest Email

CHICAGO, Feb. 15, 2024 (GLOBE NEWSWIRE) — The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy. Ms. Shivas, who joined FSR in 2021 and has served FSR as the Vice President of Research and Strategic Partnerships and the Chief Strategy Officer, has played a pivotal role in the expansive growth of FSR over the last three years.

Ms. Shivas has been instrumental in growing and diversifying the organization’s revenue, establishing and expanding pharmaceutical and regulatory partnerships to advance drug development, creating and executing influential programming, and designing and growing the FSR’s Global Sarcoidosis Clinic Alliance – a 42-member program consisting of clinics, hospitals, individual providers, patients. and caregivers committed to finding a cure and ensuring evidence-based, patient-centric care for those living with sarcoidosis. Ms. Shivas has also supported the doubling of FSR’s staff over the last 3 years through the implementation of operational systems to track revenue cycle management, data analytics, and programs’ progress and outcomes.

“Since joining FSR three years ago, Tricha has proven to be an extraordinary leader filled with passion and expertise resulting in significant advancements for FSR,” said Mary McGowan, FSR’s Chief Executive Officer. “The appointment of Tricha to the role of Chief of Staff and Strategy is a pivotal piece in our comprehensive strategy to take big, bold steps towards a brighter future for all impacted by sarcoidosis.”

“I am honored by this promotion and look forward to utilizing my expertise to help accelerate research, support patients, advance clinician understanding, and support the sarcoidosis community,” said Ms. Shivas.   “Every day I continue to be impressed with our team and volunteer leaders’ entrepreneurial spirit and dedication to deliver exceptional work in support of FSR’s mission.”

Ms. Shivas’ strengths lie in her ability to build powerful collaborations, innovative strategic approach, meticulous organization, and her adept problem-solving. Ms. Shivas will lean on her nearly 20 years of experience in academia, patient advocacy, and healthcare policy to work alongside the CEO, Governing Board of Directors, Scientific Advisory Board, and patient leaders to improve the lives of all impacted by sarcoidosis as together they continue to seek better treatments and a possible cure for sarcoidosis.

About Foundation for Sarcoidosis Research (FSR)

The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and to improving care for sarcoidosis patients through research, education, and support. For more information about FSR and to join our community, visit: stopsarcoidosis.org.

Contact:

Cathi Davis
FSR Sr. Manager of Marketing and Communications
[email protected] 

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d4ffdea4-6ed5-4397-a3d9-9aca1daa4b0c

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Paraganglioma Market Trends and Investment Opportunities 2026-2030

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 – Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

$28+ Billion Cancer Supportive Care Products Market Outlook Report, 2030

Editors Picks

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

March 30, 2026

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

March 30, 2026

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

March 30, 2026

Paraganglioma Market Trends and Investment Opportunities 2026-2030

March 30, 2026

Latest News

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

March 30, 2026

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

March 30, 2026

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 – Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

March 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version